Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![Biopharma_Watch Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1734221906151165952.png) BiopharmaWatch [@Biopharma_Watch](/creator/twitter/Biopharma_Watch) on x XXX followers
Created: 2025-07-23 15:45:02 UTC

Top Market Movers: Positive News
Full Access:
$ABVX   [65.61$]   [556.10%]   [July 23, 2025]
Abivax Announces Positive Phase X Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 En


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948046706513424601/c:line.svg)

**Related Topics**
[$abvx](/topic/$abvx)

[Post Link](https://x.com/Biopharma_Watch/status/1948046706513424601)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Biopharma_Watch Avatar BiopharmaWatch @Biopharma_Watch on x XXX followers Created: 2025-07-23 15:45:02 UTC

Top Market Movers: Positive News Full Access: $ABVX [65.61$] [556.10%] [July 23, 2025] Abivax Announces Positive Phase X Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 En

XXX engagements

Engagements Line Chart

Related Topics $abvx

Post Link

post/tweet::1948046706513424601
/post/tweet::1948046706513424601